[Siliconware Precision Industries Co., Ltd. Press Release Issued on: 2016/5/23 The Company cautions its shareholders and others considering trading its securities that the special review committee has not formally reviewed or evaluated the Proposed Transaction. There can be no assurance that any definitive agreement will be executed in relation to the Proposed Transaction or that the Proposed Transaction or any]
[May 23, 2016 IDI, Inc. Re: Common Stock registered under Registration Statement on Form S-3 Ladies and Gentlemen: We have acted as counsel to IDI, Inc., a Delaware corporation (the Company), in connection with the Securities Purchase Agreement dated May 17, 2016 (the Agreement) by and between the Company and Chardan Capital Markets, LLC, and the investors signatories thereto (the] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest Event Reported): May 23, 2016 IDI, Inc. Delaware 333-158336 77-0688094 _____________________ _____________ ______________ of incorporation) Identification No.) 2650 North Military Trail, Suite 300, Boca Raton, Florida 33431 _________________________________ ___________ 561-757-4000 Not Applicable Top of the Form Item 8.01 Other Events. Top of the Form]
[Siliconware Precision Industries Co., Ltd. Press Release Issued on: 2016/5/23 The Company cautions its shareholders and others considering trading its securities that the special review committee has not formally reviewed or evaluated the Proposed Transaction. There can be no assurance that any definitive agreement will be executed in relation to the Proposed Transaction or that the Proposed Transaction or any]
[FORM 10-Q (Mark One) ☒ March 31, 2016 For the quarterly period ended: Or ☐ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Ronghua Wang EX-32.1 4 ex32-1.htm EX-32.1] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Qinghua Liu Qinghua Liu Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm EX-32.2]
[May 23, 2016 IDI, Inc. Re: Common Stock registered under Registration Statement on Form S-3 Ladies and Gentlemen: We have acted as counsel to IDI, Inc., a Delaware corporation (the Company), in connection with the Securities Purchase Agreement dated May 17, 2016 (the Agreement) by and between the Company and Chardan Capital Markets, LLC, and the investors signatories thereto (the] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest Event Reported): May 23, 2016 IDI, Inc. Delaware 333-158336 77-0688094 _____________________ _____________ ______________ of incorporation) Identification No.) 2650 North Military Trail, Suite 300, Boca Raton, Florida 33431 _________________________________ ___________ 561-757-4000 Not Applicable Top of the Form Item 8.01 Other Events. Top of the Form]
[FORM 10-Q (Mark One) ☒ March 31, 2016 For the quarterly period ended: Or ☐ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Ronghua Wang EX-32.1 4 ex32-1.htm EX-32.1] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Qinghua Liu Qinghua Liu Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm EX-32.2]
[Dehaier Medical Announces Receipt of the Nasdaq Notification Letter The letter further states that the Company has 60 calendar days (until July 18, 2016) to submit a plan to Nasdaq setting forth how the Company plans to regain compliance with the Rule. If the Company is unable to file the Form 20-F by July 18, 2016, then the Company intends] []
[] [SEASPAN CORPORATION, AS ISSUER, TO , AS TRUSTEE INDENTURE [SUBORDINATED] DEBT SECURITIES DATED AS OF , 20 Reconciliation and tie between Trust Indenture Act of 1939 (the Trust Indenture Act) and Indenture Trust Indenture Act of 1939 Section Indenture Section 310 (a)(1) 6.8 (a)(2) 6.8 (a)(3) TIA (a)(4) Not Applicable (a)(5) TIA (b) 6.9 311 (a) TIA (b) TIA 312] [SEASPAN CORPORATION, AS ISSUER, TO , AS TRUSTEE INDENTURE CONVERTIBLE [SUBORDINATED] DEBT SECURITIES DATED AS OF , 20 Reconciliation and tie between Trust Indenture Act of 1939 (the Trust Indenture Act) and Indenture Trust Indenture Act of 1939 Section Indenture Section 310 (a)(1) 6.8 (a)(2) 6.8 (a)(3) TIA (a)(4) Not Applicable (a)(5) TIA (b) 6.9 311 (a) TIA (b) TIA] [REEDER & SIMPSON, P.C. ATTORNEYS AT LAW P.O. Box 601 RRE Commercial Center Majuro, MH 96960 Telephone: + 692-625-3602 Email: dreeder@ntamar.net r.simpson@simpson.gr May 23, 2016 Seaspan Corporation Unit 2, 7th Floor, Bupa Centre 141 Connaught Road West Hong Kong, China Ladies and Gentlemen: RMI Corporation Registration Statement Commission Securities Act a. Common Shares common shares of the Corporation (the ] [May 23, 2016 Seaspan Corporation Unit 2, 7th Floor, Bupa Centre 141 Connaught Road West Hong Kong, China Re: Registration Statement on Form F-3 filed by Seaspan Corporation Ladies and Gentlemen: Company Commission Securities Act Rules Registration Statement We have acted as counsel to Seaspan Corporation, a Marshall Islands corporation (the (a) shares of the Companys common stock, par] [Consent of Independent Registered Public Accounting Firm The Board of Directors Seaspan Corporation: We consent to the use of our reports with respect to the consolidated financial statements and the effectiveness of internal control over financial reporting incorporated by reference herein and to the reference to our firm under the heading Experts in the prospectus. Chartered Professional Accountants Vancouver, Canada]
[Dehaier Medical Announces Receipt of the Nasdaq Notification Letter The letter further states that the Company has 60 calendar days (until July 18, 2016) to submit a plan to Nasdaq setting forth how the Company plans to regain compliance with the Rule. If the Company is unable to file the Form 20-F by July 18, 2016, then the Company intends] []
